But that's not all the next seven days have in store.

Fellow golf pro Stewart Smith worked with Billy at a course in London and remembers his friend as a natural comic with a zest for life."He was a very funny guy. Great sense of humour, great sense of fun," he says.

"He had moved to Richmond Park, so I went across and worked with Billy. Imagine living in London in the mid-80s when you're mid-20s, both of you."We had some great times."Back in Mull, family friends have put a memorial bench on the course at Tobermory, where they say Billy played every day after school and every weekend from the age of 12. They remember him as "some guy".

Family friend Olive Brown says: "Every December I do have a wee sad moment, thinking he's not here. All that potential, enthusiasm and ability got caught short."Colyn and other members of Olive Gordon's family visited Lockerbie in the days after the disaster. It was a shocking scene.

"I remember the crater, this huge hole, and these little bits all over the place. It just had this smell. My God, my sister was found here. Somewhere here," he says.

In the weeks that followed, members of the local community came together to wash, press and package up the belongings of those who had died on the plane.Physicians point to multiple barriers - reaching the right health facility, getting accurate diagnostic tests, and accessing effective drugs. Cost remains a major hurdle, with many of these antibiotics priced far beyond the reach of poorer patients.

"Those who can afford these antibiotics often overuse them; those who can't, don't get them at all," says Dr Ghafur. "We need a system that ensures access for the poor and prevents misuse by the well-to-do."To improve access, these drugs must be made more affordable. To prevent misuse, stronger regulation is key.

"Ideally, every antibiotic prescription in hospitals should require a second sign-off - by an infection specialist or microbiologist," says Dr Ghafur. "Some hospitals do this, but most don't. With the right oversight, regulators can ensure this becomes standard practice."To fix the access problem and curb misuse, both smarter policies and stronger safeguards are essential, say researchers. But access alone won't solve the crisis - the pipeline of new antibiotics is drying up. The decline in antibiotic R&D - and the limited availability of existing drugs - is a global issue.